-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqISIN US28106W1036-
Editas Medicine IncBörse NasdaqISIN US28106W1036 WKN: A2AC4KSymbol EDIT
-
Editas MedicineBörse Börse BerlinEURSymbol 8EM
-
Editas MedicineBörse Börse MünchenEURSymbol 8EM
-
EDITAS MEDICINE INCBörse Börse DüsseldorfEURSymbol 8EM
-
EDITAS MEDICINE INCBörse Quotrix System der Börse DüsseldorfEURSymbol 8EM
-
EDITAS MEDICINE INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol 8EM
-
EDITAS MEDICINE INCBörse Gettex System der Börse MünchenEURSymbol 8EM
-
EDITAS MEDICINE INCBörse Börse StuttgartEURSymbol 8EM
-
Editas MedicineBörse NasdaqISIN US28106W1036 WKN: A2AC4KUSDSymbol EDIT
-
EURSymbol 8EM
-
Editas Medicine, Inc.Börse London Stock Exchange
-
ISIN US28106W1036
WKN A2AC4K
Symbol EDIT
Börse
Nasdaq Zeitzone: Europe/Berlin
Firmenname
Editas Medicine, Inc
Marktkapitalisierung
2.855.239.552 (+- 28%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
3.642.479.104 oder 2.068.000.000
Mitarbeiter
217 (+- 4%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
208 oder 226 Mitarbeiter
EBITDA -106.383.000
Buchwert 7.136
Editas Medicine outperformed den DAX um +198 % vom 03.02.2016 bis 01.09.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 30,31 EUR +1,71%
Portrait der Aktie: Editas Medicine
Das Unternehmen Editas Medicine, Inc aus USA beschäftigt 217 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Die Editas Medicine Aktie konnte seit dem 03.02.2016 eine Rendite von bemerkenswerten 265% erwirtschaften.
Das Unternehmen Editas Medicine, Inc ist nur in 9 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter Global X Genomics & Biotechnology ETF gewichtet Editas Medicine mit 3,10% im ETF.
Entdecke die 6 ETFs in denen Editas Medicine, Inc am höchsten gewichtet ist Insgesamt in 9 ETFs enthalten
Dir gefallen die Informationen zu Editas Medicine?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Editas Medicine?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Editas Medicine?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Editas Medicine?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
41 News & Informationen zur Editas Medicine Aktie
S&P, NASDAQ Set New Highs While Waiting for Jobs Report
Stocks Analysis by Zacks Investment Research covering: Cross Country Healthcare Inc, Pacific Biosciences of California, Materion Corporation, Editas Medicine Inc. Read Zacks Investment Research's latest article on Investing.com
Thursday Afternoon Analyst Upgrades and Downgrades: Bath & Body Works, Editas, GoDaddy, PetMed, Qorvo and More – 24
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including Bath & Body Works, Editas Medicine, GoDaddy, PetMed Express and Qorvo.
Cathie Wood’s ARK Invest Buys for 8
Here's a look at the ARK Invest buys for August 4, 2021.
Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript
EDIT earnings call for the period ending June 30, 2021.
10 Best Up and Coming Stocks to Invest In
In this article, we discuss the 10 best up and coming stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to the…
The Top 2 Stocks to Buy to Play the Emerging Exoskeleton Megatrend
InvestorPlace – Stock Market News, Stock Advice & Trading Tips Remember the 2014 Tom Cruise film Edge of Tomorrow? Source: Shutterstock Great…
Green Alpha Advisors, LLC Buys Hudson Pacific Properties Inc, ASML Holding NV, Kilroy Realty Corp, Sells Tesla Inc, Daqo New Energy Corp, Alphabet Inc
GuruFocus Article or News written by insider and the topic is about:
Chevy Chase Trust Holdings, Inc. Buys Franco-Nevada Corp, ChampionX Corp, Nasdaq Inc, Sells iShares Gold Trust, Splunk Inc, Seagate Technology Holdings PLC
GuruFocus Article or News written by insider and the topic is about:
2U Inc (TWOU): Are Hedge Funds Right About This Stock?
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided…
Hedge Funds Are Crazy About Editas Medicine, Inc. (EDIT)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However…
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.
After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding
It's a good time to be a gene-editing company.
Where Do Hedge Funds Stand On Cornerstone OnDemand, Inc. (CSOD)?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed…
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher?
Here's What Drove Gene Editing Stocks Higher This Week
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
Gene Editing Stocks Are Worth A Look After Intellia’s Big Breakthrough
Intellia Therapeutics – a gene-editing company co-founded by CRISPR pioneer and Nobel prize winner Jennifer Doudna – indicated that NTLA-2001, its experimental treatment for transthyretin amyloidosis provided very promising results in an early state trial. Although the study was small, including…
Editas Medicine: Undervalued Gene-Editing Stock (NASDAQ:EDIT)
The rally for gene editing stocks has entered its third day. Click here to read about Editas Medicine's valuation and why it is a better fit than peers.
Major Indices Surge Double Digits in First Half of 2021
Stocks Analysis by Zacks Investment Research covering: Micron Technology Inc, Sterling Construction Company Inc, Virtu Financial Inc, Ooma Inc. Read Zacks Investment Research's latest article on Investing.com
New Gene Editing Trial Results Bump the ARKG ETF
Shares of Intellia Therapeutics surged Monday after the firm announced positive results for an in vivo genome editing therapy known as NTLA-2001.
Global Gene Therapy Market To Reach $2.7 Billion By 2026
SAN FRANCISCO, June 29, 2021 /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today
Intellia Gains After Strong Results in Landmark Crispr Study
(Bloomberg) — In a milestone for gene therapy, drugmakers Intellia Therapeutics Inc. and Regeneron Pharmaceuticals Inc. reported results from the first clinical trial using Nobel Prize-winning Crispr technology to treat disease inside the human body.
Why Editas Medicine Stock Is Jumping Today
Good news for Intellia was viewed as good news for Editas.
Intellia Soars On Positive Results In Gene-Editing Treatment By Investing.com
Intellia Soars On Positive Results In Gene-Editing Treatment
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ:NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceutica…
Pre-market Movers: NTLA, ABUS, ATOS, GTEC…
The following are some of the stocks making big moves in Monday's pre-market trading (as of 4.41 A.M.).
Potential Game-changing Bio-Technology
There are some exciting developments in the biotech arena that could potentially be game-changers in their respective fields.
Why Editas Medicine Stock Is Jumping 13.9% This Week
The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate.
Nasdaq Stays Flat as Workhorse Drives Higher, Editas Sinks
Investors are trying to figure out which stocks have the best prospects.
Why Editas Medicine Stock Is Getting Crushed Today
Investors are running for the hills following this analyst take on the biotech's prospects.
Alibaba, Nuance, Microsoft: What to Watch When the Market Opens
S&P 500 futures point to the market opening below last week's record highs
Opinion: Biotech stocks are a buy — especially these 18 picks
The sector's recent pullback offers an chance to get into exciting areas of biotech research like gene editing and oncology at better prices.
Ark Invest Stocks With Big Moves Last Week – 24
Commentary from Ark Invest: We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful. Grayscale Bitcoin Investment Trust (GBTC) Down 16% Grayscale Bitcoin Investment Trust, a trust tracking bitcoin’s market […]
Editas Medicine (EDIT) Gains As Market Dips: What You Should Know
Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.
A reinvigorated Alzheimer's treatment and gene-therapy setbacks: 3 winners and 3 losers from the healthcare industry's most important event of the year
Gene therapy biotechs were overshadowed and struggled, while a highly debated theory on treating Alzheimer's disease got a boost.
Despite A 4x Rise, Editas Medicine May Continue To Trend Higher
Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, looks attractive and it can see more upside from the current levels…
BGNE Teams Up With NVS, Editas Slumps Over 15%, LLY's Drug Shines In TRAILBLAZER-ALZ, MESO On Watch
Today's Daily Dose brings you news about Lilly's Alzheimer's disease trial data, BeiGene's collaboration agreement with Novartis, Mesoblast's encouraging results from phase III trial of Rexlemestrocel-L in patients with chronic heart failure, and the resignation of Editas' Chief Scientific Officer.
CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism’s genome, helping to replace the defective genes responsible for a medical condition with healthy versions. This technology is being used to develop treatments for a…
Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla
Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla, Stocks: TSLA,EDIT,CRSP,NTLA,ARKG,PACB,FATE,NVTA,IOVA,EXAS, release date:Jan 08, 2021
Stocks That Hit 52-Week Highs On Friday
This morning 470 companies set new 52-week highs.
Facts of Interest: Tesla (NASDAQ:TSLA) was the largest firm on a market cap basis to set a …
3 Biotech Stocks That Could Double Your Money in 2021
Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.